U.S. flag

An official website of the United States government

NC_000023.10:g.(?_152014869)_(155171615_?)del AND 3-Methylglutaconic aciduria type 2

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Oct 4, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003119101.4

Allele description [Variation Report for NC_000023.10:g.(?_152014869)_(155171615_?)del]

NC_000023.10:g.(?_152014869)_(155171615_?)del

Genes:
Variant type:
Deletion
Cytogenetic location:
Xq28
Genomic location:
ChrX: 152014869 - 155171615 (on Assembly GRCh37)
Preferred name:
NC_000023.10:g.(?_152014869)_(155171615_?)del
HGVS:
NC_000023.10:g.(?_152014869)_(155171615_?)del

Condition(s)

Name:
3-Methylglutaconic aciduria type 2 (BTHS)
Synonyms:
Barth syndrome; 3-methylglutaconicaciduria type II; MGA type II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010543; MedGen: C0574083; Orphanet: 111; OMIM: 302060

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003790638Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Oct 4, 2022)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity.

Xing Y, Ichida F, Matsuoka T, Isobe T, Ikemoto Y, Higaki T, Tsuji T, Haneda N, Kuwabara A, Chen R, Futatani T, Tsubata S, Watanabe S, Watanabe K, Hirono K, Uese K, Miyawaki T, Bowles KR, Bowles NE, Towbin JA.

Mol Genet Metab. 2006 May;88(1):71-7. Epub 2006 Jan 19.

PubMed [citation]
PMID:
16427346

Exon-level array CGH in a large clinical cohort demonstrates increased sensitivity of diagnostic testing for Mendelian disorders.

Aradhya S, Lewis R, Bonaga T, Nwokekeh N, Stafford A, Boggs B, Hruska K, Smaoui N, Compton JG, Richard G, Suchy S.

Genet Med. 2012 Jun;14(6):594-603. doi: 10.1038/gim.2011.65. Epub 2012 Mar 1.

PubMed [citation]
PMID:
22382802
See all PubMed Citations (5)

Details of each submission

From Invitae, SCV003790638.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

A gross deletion of the genomic region encompassing the full coding sequence of the TAZ gene has been identified. Loss-of-function variants in TAZ are known to be pathogenic (PMID: 16427346, 22382802, 23409742). The boundaries of this event are unknown as they extend beyond the assayed region for this gene and therefore may encompass additional genes. A similar copy number variant has been observed in individual(s) with Barth syndrome (PMID: 19396829). For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 26, 2024